Description

Actemra 400 mg/20 ml Injection (Tocilizumab) – Uses, Dosage, Side Effects & Price in Pakistan

Actemra (Tocilizumab) is a prescription biologic medication available in Pakistan as an injectable solution at 20 mg/ml, with 400 mg per 20 ml vial. It is primarily used to treat rheumatoid arthritis (RA), cytokine release syndrome (CRS), juvenile idiopathic arthritis (JIA), giant cell arteritis (GCA), and severe COVID-19-related inflammation.

---

Key Uses of Actemra (Tocilizumab)

• ✅ Rheumatoid Arthritis (RA): Reduces joint inflammation, prevents joint damage, and improves physical function.

• ✅ Juvenile Idiopathic Arthritis (JIA): Effective for systemic (SJIA) and polyarticular (PJIA) forms in children.

• ✅ Giant Cell Arteritis (GCA): Helps control inflammation in patients with this autoimmune vascular condition.

• ✅ Cytokine Release Syndrome (CRS): Treats severe immune responses caused by certain therapies like CAR-T cell treatment.

• ✅ COVID-19 Treatment: Reduces excessive inflammation in hospitalized adult patients with severe COVID-19.

---

How Actemra Works

Actemra is a humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R).

Mechanism of Action:

• IL-6 Inhibition: Blocks IL-6 from binding to its receptor, reducing inflammation in autoimmune conditions.

• Reduction of Inflammatory Markers: Lowers C-reactive protein (CRP) and serum amyloid A levels.

• Immune Modulation: Helps regulate overactive T-cell and B-cell activity, minimizing tissue damage.

---

Actemra Ingredients

Active Ingredient:

• Tocilizumab – IL-6 receptor antagonist

Inactive Ingredients (IV Formulation):

• Disodium phosphate dodecahydrate

• Sodium dihydrogen phosphate dihydrate

• Polysorbate 80

• Sucrose

• Water for Injection

---

Dosage and Administration

Rheumatoid Arthritis (RA):

• IV Infusion: 4 mg/kg every 4 weeks; may increase to 8 mg/kg if response is inadequate.

• Subcutaneous Injection: 162 mg once every 2 weeks; weekly dosing may be considered based on response.

Giant Cell Arteritis (GCA):

• Initial IV dose: 8 mg/kg

• Maintenance: 4 mg/kg every 4 weeks

Juvenile Idiopathic Arthritis (JIA):

• Weight-based dosing determined by a healthcare provider.

Administration:

• IV infusion should be done in a healthcare setting

• Subcutaneous injections can be administered at home with proper guidance

---

Storage Instructions

• IV Formulation: Store in original carton at 2–8°C (36–46°F), protect from light, do not freeze.

• Subcutaneous Formulation: Refrigerate at 2–8°C; can remain at room temperature (up to 25°C) for 14 days. Avoid direct sunlight or heat.

---

Side Effects and Precautions

Common Side Effects:

• Upper respiratory tract infections

• Headache

• Increased liver enzymes

• Injection site reactions

Serious Precautions:

• Avoid use during active infections

• Monitor blood cell counts and liver function regularly

• Risk of gastrointestinal perforation in patients with a history of GI issues

• Hypersensitivity reactions including anaphylaxis may occur

• Avoid live vaccines while on treatment

• Use with caution during pregnancy or breastfeeding

Dietary Considerations:

• Avoid raw or undercooked eggs, meats, and fish

• Avoid unpasteurized dairy products and raw sprouts

• Maintain proper food hygiene to reduce infection risk

• Limit alcohol consumption and maintain hydration

Recommended Foods:

• Fatty fish rich in omega-3 fatty acids

• Fresh fruits and vegetables

• Nuts, seeds, and whole grains

• Anti-inflammatory spices like ginger and turmeric

• Olive oil and water for hydration

---

Patient Experiences

• Actemra has an average user rating of 6.9/10

• Many patients report reduced joint pain, stiffness, and fatigue

• Improvements in daily activities and overall quality of life have been noted